Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
Espoo, Finland, 2 June 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today provides an update on preparations for the Phase 2a proof-of-concept efficacy study of HER-096, its lead candidate for the treatment of Parkinson's disease, ahead of its webcast being hosted later today at 13.00 EEST (12:00 CEST).
Espoo, Finland, 2 June 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today provides an update on preparations for the Phase 2a proof-of-concept efficacy study of HER-096, its lead candidate for the treatment of Parkinson's disease, ahead of its webcast being hosted later today at 13.00 EEST (12:00 CEST).
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.